Noninferiority Trial Design: Opportunities and Challenges.

J Hand Surg Am · Nov 2022 · Review

Adidharma W, Nguyen SN, Waljee JF

Department of Surgery, Section of Plastic Surgery, University of Michigan, MI

General Orthopaedics

SUMMARY — THE REDUCTIONThis review explains the design, analysis, and interpretation nuances of noninferiority trials, which test whether a new treatment is not unacceptably worse than standard care when placebo-controlled superiority trials are unethical.
Abstract, as published

Defining treatment effectiveness is the foundation of evidence-based practice. Most studies comparing the effectiveness of treatment options involve superiority designs in which a treatment is compared against a placebo, standard care, or an alternative treatment. However, in scenarios in which it is not ethical to consider these options, noninferiority designs can be considered. Noninferiority (NI) trials aim to demonstrate that a new treatment is not unacceptably worse than a standard treatment. Noninferiority is determined relative to a noninferiority margin, which is the difference between the test and active control treatment that is not unacceptably clinically inferior. However, there are important considerations with respect to the design, analysis, and interpretation of NI studies, which differ from superiority trials. This review will outline the key components of NI trials, how to interpret the findings, and understand their nuances and potential limitations.

Featured in the 2026-08-17 issue.

← Blood Flow Restriction Therapy: Where We Are and Where We Are…A history of eponym usage in hip and pelvis radiography part … →

The Reduction is a free email digest of newly published orthopaedic literature — a handful of new papers in the subspecialties you choose, each summarized like this one. Subscribe free or browse the archive.